Abstract | BACKGROUND & AIMS:
Inflammatory bowel diseases (IBDs) that encompass both ulcerative colitis and Crohn's disease are a major public health problem with an etiology that has not been fully elucidated. There is a need to improve disease outcomes and preventive measures by developing new effective and lasting treatments. Although polyunsaturated fatty acid metabolites play an important role in the pathogenesis of several disorders, their contribution to IBD is yet to be understood. METHODS: RESULTS: A significant reduction of PGI2 in IBD patient biopsies was identified. PGI2 treatment reduced colonic inflammation, increased occludin expression, decreased caspase-3 cleavage and intestinal permeability, and prevented colitis development in DSS-induced mice. Using colonic explants from mouse and human control subjects, the staurosporine-induced increase in paracellular permeability was prevented by PGI2. PGI2 also induced the membrane location of occludin and reduced the permeability observed in colonic biopsies from IBD patients. CONCLUSIONS: The present study identified a PGI2 defect in the intestinal mucosa of IBD patients and demonstrated its protective role during colitis.
|
Authors | Camille Pochard, Jacques Gonzales, Anne Bessard, Maxime M Mahe, Arnaud Bourreille, Nicolas Cenac, Anne Jarry, Emmanuel Coron, Juliette Podevin, Guillaume Meurette, Michel Neunlist, Malvyne Rolli-Derkinderen |
Journal | Cellular and molecular gastroenterology and hepatology
(Cell Mol Gastroenterol Hepatol)
Vol. 12
Issue 3
Pg. 1037-1060
( 2021)
ISSN: 2352-345X [Electronic] United States |
PMID | 33971327
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Fatty Acids, Unsaturated
- Tight Junction Proteins
- Dextran Sulfate
- Epoprostenol
|
Topics |
- Adult
- Aged
- Animals
- Caco-2 Cells
- Case-Control Studies
- Colitis
(chemically induced, drug therapy, genetics, metabolism)
- Dextran Sulfate
(adverse effects)
- Disease Models, Animal
- Epoprostenol
(administration & dosage, pharmacology)
- Fatty Acids, Unsaturated
(metabolism)
- Female
- Humans
- Inflammatory Bowel Diseases
(chemically induced, drug therapy, metabolism, surgery)
- Intestinal Mucosa
(cytology, drug effects, metabolism)
- Male
- Metabolomics
- Mice
- Mice, Inbred C57BL
- Middle Aged
- Permeability
(drug effects)
- Tight Junction Proteins
(genetics)
- Young Adult
|